Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Shelter Pharma's Revenue for the
six
months ended in Mar. 2026 was ₹398.4 Mil. Shelter Pharma's average Accounts Receivable for the
six
months ended in Mar. 2026 was ₹113.7 Mil.
Hence, Shelter Pharma's Receivables Turnover for the
six
months ended in Mar. 2026 was 3.50.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Shelter Pharma Receivables Turnover Related Terms
Shelter Pharma Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Shelter Pharma's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:543963 vs ZTS: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shelter Pharma's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shelter Pharma Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shelter Pharma's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Shelter Pharma's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shelter Pharma (BOM:543963) has a Receivables Turnover of 3.50 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Shelter Pharma and its competitors. According to the industry distribution chart, Shelter Pharma ranks #273 out of 948 companies in the Drug Manufacturers industry, placing it in the top 28.8%.
Is Shelter Pharma's Receivables Turnover too high?
Shelter Pharma's current Receivables Turnover is 3.50. The Drug Manufacturers industry median Receivables Turnover is 5.08. Shelter Pharma's value of 3.50 is 31.1% below this industry median. Based on the distribution chart, Shelter Pharma ranks #273 out of 948 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Shelter Pharma has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Shelter Pharma's Receivables Turnover compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shelter Pharma ranks #273 out of 948 companies for Receivables Turnover. This puts Shelter Pharma in the upper half of its industry. The industry median Receivables Turnover is 5.08. Shelter Pharma's value of 3.50 is 31.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.08, based on 948 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shelter Pharma's current Receivables Turnover of 3.50 is 31.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Shelter Pharma and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shelter Pharma's current Receivables Turnover is 3.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shelter Pharma stock overvalued right now?
Based on GuruFocus' analysis, Shelter Pharma (BOM:543963) is currently considered Possible Value Trap. The stock's GF Value™ is ₹57.49, compared to a current price of ₹31.60 — trading 45% below its estimated fair value. The current Receivables Turnover is 3.50 and 31.1% below the Drug Manufacturers industry median of 5.08. Shelter Pharma's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Shelter Pharma (BOM:543963), the current Receivables Turnover is 3.50 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shelter Pharma (BOM:543963) Overvalued in 2026?
Based on GuruFocus' analysis, Shelter Pharma stock appears to be undervalued.
The current stock price of ₹31.60 is trading 45% below its estimated GF Value™ of ₹57.49.
GuruFocus considers Shelter Pharma to be Possible Value Trap.
Key valuation signals for BOM:543963:
Receivables Turnover: 3.50
GF Value™: ₹57.49 vs. price of ₹31.60 (45% below fair value)
Industry Position: 31.1% below the Drug Manufacturers median (#273 of 948)
No single metric tells the full story. See the BOM:543963 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shelter Pharma Ltd focuses in manufacturing herbal products with a well-built presence in Human Pharma as well as the Veterinary space. It is present in majority of the non-critical segments of human and veterinary pharma through its well-spread portfolio. Its products include tablets, syrups, baby drops, barley water, oils, powders, ointments, etc.
69GF Score
Get the complete analysis for BOM:543963
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543963 has been successfully added to your 
